EcoR1 Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

EcoR1 Capital’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,346,475	Closed	-$21.9M	–	65
2024 Q2	$21.9M	Sell	1,346,475 -4,645,004	-78%	-$75M	0.67%	32
2024 Q1	$111M	Hold	5,991,479	–	–	2.8%	12
2023 Q4	$188M	Hold	5,991,479	–	–	4.87%	6
2023 Q3	$125M	Hold	5,991,479	–	–	4.21%	7
2023 Q2	$143M	Hold	5,991,479	–	–	3.52%	9
2023 Q1	$113M	Hold	5,991,479	–	–	3.63%	9
2022 Q4	$95.4M	Hold	5,991,479	–	–	2.9%	10
2022 Q3	$98M	Hold	5,991,479	–	–	2.89%	10
2022 Q2	$84.4M	Hold	5,991,479	–	–	2.91%	11
2022 Q1	$145M	Buy	5,991,479 +2,930,886	+96%	+$70.9M	4.54%	7
2021 Q4	$71.4M	Buy	+3,060,593	New	+$61.6M	2.28%	13
2020 Q3	–	Sell	-135,413	Closed	-$6.56M	–	50
2020 Q2	$6.56M	Sell	135,413 -188,476	-58%	-$9.05M	0.48%	31
2020 Q1	$13.7M	Sell	323,889 -176,111	-35%	-$7.26M	1.43%	22
2019 Q4	$21.4M	Buy	+500,000	New	+$21.8M	1.93%	19

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

EcoR1 Capital's ACAD Position: Q3 2024 in Review

EcoR1 Capital sold out of Acadia Pharmaceuticals (ACAD) in Q3 2024, closing a stake of 1,346,475 shares — an estimated $21.9M sold.

EcoR1 Capital first reported a position in ACAD in Q4 2019 and held it in 14 quarters. The position peaked at $188M in Q4 2023. 256 funds tracked by Wall St. Rank hold ACAD as of Q3 2024.

EcoR1 Capital reported no remaining Acadia Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
EcoR1 Capital sold 1,346,475 Acadia Pharmaceuticals shares in Q3 2024, an estimated $21.9M.
EcoR1 Capital first reported a position in Acadia Pharmaceuticals in Q4 2019 and held it in 14 quarters.
EcoR1 Capital's Acadia Pharmaceuticals position peaked at $188M in Q4 2023.
256 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2024.

Based on EcoR1 Capital's 13F filing for Q3 2024, filed 14 Nov 2024.